Nebula Research & Development LLC Invests $2.03 Million in Chemed Co. (NYSE:CHE)

Nebula Research & Development LLC acquired a new stake in Chemed Co. (NYSE:CHE - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,838 shares of the company's stock, valued at approximately $2,033,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Keyvantage Wealth LLC purchased a new position in Chemed in the 4th quarter valued at about $265,000. Integrated Wealth Concepts LLC boosted its position in Chemed by 25.5% in the 4th quarter. Integrated Wealth Concepts LLC now owns 8,668 shares of the company's stock valued at $4,592,000 after buying an additional 1,759 shares during the last quarter. Stifel Financial Corp lifted its position in shares of Chemed by 0.6% during the fourth quarter. Stifel Financial Corp now owns 27,145 shares of the company's stock worth $14,381,000 after purchasing an additional 149 shares during the last quarter. MetLife Investment Management LLC lifted its position in shares of Chemed by 8.5% during the fourth quarter. MetLife Investment Management LLC now owns 8,511 shares of the company's stock worth $4,509,000 after purchasing an additional 666 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Chemed by 10.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 199,254 shares of the company's stock worth $105,564,000 after purchasing an additional 18,584 shares during the last quarter. 95.85% of the stock is owned by hedge funds and other institutional investors.

Chemed Price Performance

NYSE:CHE traded down $2.28 during midday trading on Wednesday, reaching $572.68. 47,530 shares of the company traded hands, compared to its average volume of 115,262. Chemed Co. has a twelve month low of $512.12 and a twelve month high of $623.60. The firm has a market capitalization of $8.37 billion, a price-to-earnings ratio of 28.94, a price-to-earnings-growth ratio of 2.15 and a beta of 0.49. The company has a fifty day moving average price of $588.34 and a 200 day moving average price of $566.62.

Chemed (NYSE:CHE - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The company reported $5.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.04. Chemed had a return on equity of 27.86% and a net margin of 12.69%. The business had revenue of $646.94 million during the quarter, compared to analyst estimates of $641.78 million. During the same quarter in the previous year, the firm posted $5.20 EPS. The business's revenue for the quarter was up 9.8% compared to the same quarter last year. On average, equities research analysts forecast that Chemed Co. will post 21.43 earnings per share for the current fiscal year.

Chemed Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, March 14th. Shareholders of record on Monday, February 24th were given a dividend of $0.50 per share. The ex-dividend date was Monday, February 24th. This represents a $2.00 dividend on an annualized basis and a yield of 0.35%. Chemed's dividend payout ratio (DPR) is presently 9.74%.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on CHE shares. StockNews.com raised shares of Chemed from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Royal Bank of Canada increased their price target on shares of Chemed from $667.00 to $674.00 and gave the stock an "outperform" rating in a research report on Monday.

Insiders Place Their Bets

In other news, CEO Kevin J. Mcnamara sold 2,000 shares of the company's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $593.67, for a total value of $1,187,340.00. Following the completion of the sale, the chief executive officer now owns 102,679 shares in the company, valued at $60,957,441.93. This represents a 1.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 3.29% of the stock is currently owned by insiders.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.